BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
BeiGene’s BTKi is approved in more than 65 markets globallyBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKI